Xeris Biopharma (NASDAQ:XERS) Stock: Insider Beth Hecht Sells 25,000 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total transaction of $255,750.00. Following the completion of the sale, the insider owned 1,086,130 shares in the company, valued at approximately $11,111,109.90. The trade was a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Thursday, October 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $9.41, for a total transaction of $156,827.06.
• On Tuesday, September 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.49, for a total transaction of $141,494.34.

Xeris Biopharma Price Performance

XERS stock opened at $13.08 on Friday. The company has a 50 day simple moving average of $9.49 and a 200 day simple moving average of $7.58. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of -118.91 and a beta of 0.61. Xeris Biopharma Holdings, Inc. has a 1 year low of $5.25 and a 1 year high of $13.74. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The firm had revenue of $107.23 million for the quarter, compared to analyst estimates of $101.68 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. Research analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

Xeris Biopharma News Summary

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Xeris reported third-quarter earnings of $0.06 per share, beating the $0.03 consensus estimate, while revenue of $107.23 million topped expectations of $101.68 million. The better-than-expected results were a key near-term catalyst. Xeris Biopharma Shares Jump After Q3 Results Top Estimates
• Positive Sentiment: CEO John Shannon reportedly said Recorlev could approach $1 billion in annual sales three to four years earlier than previously expected, strengthening the company’s long-term growth story. Xeris CEO Sees Recorlev Nearing $1B in Annual Sales
• Neutral Sentiment: Several executives reported selling shares at $10.23 under pre-arranged Rule 10b5-1 plans. The reported sales were relatively small compared with their remaining holdings, which tempers the significance of the transactions. Xeris Insider Sale

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Barclays lifted their price target on Xeris Biopharma from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, October 6th. Leerink Partners boosted their price target on Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. Finally, Wall Street Zen raised Xeris Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.20.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in Xeris Biopharma during the second quarter worth $115,042,000. Wellington Management Group LLP lifted its holdings in Xeris Biopharma by 8.9% in the second quarter. Wellington Management Group LLP now owns 2,365,103 shares of the company’s stock valued at $18,732,000 after buying an additional 193,749 shares during the period. Legal & General Group Plc acquired a new position in Xeris Biopharma in the second quarter valued at $15,941,000. Parkman Healthcare Partners LLC bought a new stake in Xeris Biopharma during the second quarter valued at $14,316,000. Finally, Algert Global LLC boosted its position in Xeris Biopharma by 50.6% during the second quarter. Algert Global LLC now owns 1,742,942 shares of the company’s stock valued at $13,804,000 after acquiring an additional 585,984 shares during the last quarter. 42.75% of the stock is owned by institutional investors.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.